Tessa Mair
Tessa Mair
Manjulika Das
Manjulika Das
Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study [0.03%]
针对吉隆比亚恶性疟原虫的青蒿素不完全耐药性的临床、分子和体外证据：前瞻性多中心监测研究
Buze Chala,Lucien Platon,Yssimini Nadège Guillène Tibiri et al.
Buze Chala et al.
Background: Artemisinin partial resistance (ART-R) has been confirmed in four sub-Saharan African countries since 2020, but evidence from Ethiopia is limited to molecular surveys without phenotypic confirmation. We aimed ...
Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16-26 years in Japan: a randomised, double-blind, placebo-controlled trial [0.03%]
九价人乳头瘤病毒疫苗在日本16至26岁男性中的有效性和免疫原性及安全性：一项随机双盲安慰剂对照试验
Koji Hisamoto,Masaki Yamanaka,Masayasu Nomura et al.
Koji Hisamoto et al.
Background: Efficacy of the nine-valent human papillomavirus (9vHPV; HPV6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine was shown in females and inferred for males through immunobridging. We evaluated the efficacy of the 9...
Congolese hospital staff cohort admitted with infectious symptoms in the setting of the Bundibugyo virus outbreak, April and May 2026, Bunia, DR Congo [0.03%]
2026年4月至5月刚果民主共和国布尼亚市布迪古约病毒疫情背景下因感染症状住院的刚果医院工作人员群组
Patrick LaRochelle,Melinda McKnight,Ufoymungo Ucama Patrick et al.
Patrick LaRochelle et al.
A review of Bundibugyo virus and the 2026 outbreak: lessons for epidemic preparedness [0.03%]
布ン迪波戈病毒回顾及2026年疫情暴发的启示：传染病大流行防范措施反思
Krutika Kuppalli,Placide Mbala,Jake Dunning
Krutika Kuppalli
The ongoing 2026 outbreak of Ebola virus disease caused by Bundibugyo virus (BDBV) in the Democratic Republic of the Congo and Uganda has renewed attention to one of the least studied human-pathogenic orthoebolaviruses. Since its discovery ...
Priya Venkatesan
Priya Venkatesan